SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is under pressure amid a selloff in AI infrastructure stocks, as traders focus on its heavy debt, costly financing needs, and whether its contracted demand can support further growth. Bears fear dilution or default, while dip buyers point to the backlog and Nvidia ties; Goldmans upgrade and ARKs buying have not resolved the debate.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is drawing attention amid a steep selloff and negative political sentiment surrounding Trump, with traders pointing to his reported record-low approval and approaching midterms as potential headwinds. The discussion is overwhelmingly bearish, though a few traders describe the decline as a speculative buying opportunity.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs upcoming Q3 report is the dominant focus, with traders watching for signs that subscriber growth and viewer engagement are holding up, alongside guidance on advertising and margins. The stocks weakness and analyst target cuts have fueled bearish calls for more downside, while some traders see subdued expectations as a setup for a rebound.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Ciphers steep selloff and fresh 52-week lows are driving discussion, with traders focused on dilution and financing concerns around its convertible-note offering, alongside broader scrutiny of AI data-center costs. Bearish reactions criticize management and the share overhang, while bulls point to long-term AI infrastructure demand and data-center contracts as reasons for optimism.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is drawing attention after a sharp, volatile memory-stock selloff tied to concerns about Chinese competition, the durability of AI-driven demand, and foreign outflows from South Korea; a rebound has renewed dip-buying. Traders disagree on whether the decline is an overreaction to near-term fears or a warning that the memory cycle is normalizing.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos steep selloff and an analysts sharp price-target cut are driving discussion, with traders debating whether the decline reflects stretched valuation and resetting growth expectations or broader weakness in defense and drone stocks. Some remain bullish on contract momentum and long-term demand for unmanned systems, while others are frustrated that positive business updates have not steadied the share price.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Attention is centered on Vicors upcoming quarterly results, with traders pointing to two Q3 growth-guidance increases tied to higher royalties from its Vertical Power Delivery licenses. The community is split between bullish earnings expectations and dip-buying, and concerns about volatility and the stocks history of post-earnings pullbacks.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares have fallen sharply to post-IPO lows, with traders pointing to lockup-related share supply, insider selling and a TD Cowen price-target cut as sources of pressure. The conversation is largely bearish over valuation, growth and customer concentration, though some investors see the selloff as an oversold buying opportunity and remain bullish on the companys AI-chip technology.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

CRDO is drawing attention for a sharp, volatile selloff alongside weakness across AI and semiconductor stocks; traders cite risk-off trading, margin pressure, valuation concerns, and insider selling, though no single cause is established. Bulls view the decline as a pullback in an AI-data-center connectivity business with long-term demand potential, while bears question its premium valuation and selling by executives.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Morgan Stanley named Amazon a top pick, citing stronger AWS growth prospects tied to AI demand and Nvidia GPU deployments, prompting a sharp share-price rally. Traders largely welcomed the upgrade, while others questioned whether the gains would hold and pointed to earnings and nearby resistance as tests.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

(RTTNews) - On Friday, Outlook Therapeutics (OTLK), a biopharmaceutical company developing and commercializing LYTENAVA for retinal diseases, announced Greg DiPasquale as Chief Commercial Officer...

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp

Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.

Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call

Outlook Therapeutics (NASDAQ:OTLK) released third-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below.
This transcript is brought to you by Benzinga APIs. For real-timeread more...

Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Outlook Therapeutics, Inc. (OTLK) delivered earnings and revenue surprises of 0.00% and -99.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Outlook Therapeutics (NASDAQ: OTLK) to release Q3 earnings on Aug. 14. Analysts expect a loss of 8 cents/share. Analysts rate it Neutral or Buy.read more...

Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates

Zealand Pharma AS (ZLDPF) delivered earnings and revenue surprises of +2,150.00% and +756.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Why Did OTLK Stock Crash In Pre-Market Today?

Equity

Outlook Therapeutics is looking to sell about 55.6 million common shares, accompanied by warrants, at a 10% discount over the stock’s closing price on Wednesday.

OTLK Up More Than 300% in 3 Months: Here's What You Should Know

Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead of its planned U.S. launch by year-end.

iRhythm Holdings, Inc. (IRTC) Tops Q2 Earnings and Revenue Estimates

IRHYTHM HLDGS (IRTC) delivered earnings and revenue surprises of +5,900.00% and +2.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

This account has been verified as an official OTLK representative.

Verified Account

Outlook Therapeutics

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Outlook Therapeutics Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Outlook plans to use the funds, alongside its existing cash, to support the U.S. commercial launch of its eye drug Lytenava.</li><li>Lytenava received U.S. Food and Drug Administration approval for wet age-related macular degeneration last month.</li><li>Wall Street is expecting a third-quarter loss of $0.07 per share on Friday, narrower than last year’s $0.44 per share loss, according to Fiscal.ai.</li></ul>Shares of Outlook Therapeutics (OTLK) tanked nearly 24% in pre-market trading on Thursday, after the biotech firm announced a discounted share offering to fund the commercial launch of its recently approved eye drug in the U.S.<a href="https://stocktwits.com/symbol/OTLK">OTLK stock</a> is tracking its third successive decline.<h2 class="st-heading-2">Offering At A 10% Discount</h2>Outlook Therapeutics is looking to sell about 55.6 million common shares, each accompanied by a warrant to purchase another share, at a combined price of $0.99. This represents a 10% discount over the stock’s closing price on Wednesday.The warrants carry an exercise price of $1.10 and expire after five years. Underwriters also have a 30-day option to purchase up to 8.3 million additional shares and an equal number of warrants. The offering is expected to close on Aug. 14, 2026.Outlook expects gross proceeds of roughly $55 million, which it plans to use, alongside its existing cash, to support the U.S. commercial launch of Lytenava as well as for general corporate purposes.<h2 class="st-heading-2">Lytenava Set For U.S. Launch&nbsp;</h2>Last month, the U.S. Food and Drug Administration (FDA) <a href="https://stocktwits.com/news-articles/markets/equity/otlk-fda-wet-amd-drug-analysts-see-upside/cZZx4zAR7CX">approved</a> Lytenava for wet age-related macular degeneration. Outlook describes it as the only FDA-approved Bevacizumab formulation developed specifically for use in the eye.The approval marked a turnaround after the FDA rejected Outlook’s application in December 2025 and requested additional evidence. Following an appeal, the agency’s Office of New Drugs concluded in May that no further clinical trials were needed.Lytenava is already approved in the EU and U.K., and the company expects a U.S. launch before year-end.<h2 class="st-heading-2">OTLK Q3 Earnings Due Friday</h2>Meanwhile, the company reports third-quarter results on Friday, with Wall Street expecting a loss of $0.07 per share, narrower than last year’s $0.44 per share loss, according to Fiscal.ai. The stock has a 12-month price target of $5.40, according to Koyfin data, while three of the four analysts covering the stock have a ‘Buy’ rating and one ‘hold’ rating.<h2 class="st-heading-2">Retail Remains Bearish On OTLK</h2>Retail sentiment surrounding OTLK on Stocktwits remained in the ‘bearish’ zone over the past 24 hours, amid a 330% jump in message volumes.One user said the company didn’t raise enough funds.<stembedurl>https://stocktwits.com/HarmonyPioneer67/message/661747443</stembedurl>Another user felt the offering should have been carried out when the stock traded around $1.60.<stembedurl>https://stocktwits.com/Racsoracso/message/661743798</stembedurl>The stock has seen strong buying interest so far in 2026, gaining over 60%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Outlook Therapeutics is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

SPDR S&P Biotech ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$0.493
Prev Close	$0.4882
Open	$0.4903
Dividend Yield	0.00%
50-Day Moving Average	$0.6609
Beta	1.00
Avg. Volume	4.4M
PE Ratio	-0.45

52-Week High	$2.54
52-Week Low	$0.1611
Market Capitalization	$118.85M
EPS (Annual)	-$1.79
Price to Book	-8.87
Revenue Per Employee	$83,149.12

Feed

News

Sentiment

Earnings

Fundamentals

Info

OTLK Fundamentals